#Coherus BioSciences $CHRS announced that the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office ruled in favor of the company’s petitions for inter partes review of AbbVie’s $ABBV ‘135 patent.
“The #PTAB’s decision invalidates all claims of the patent that were directed to a method for treating rheumatoid arthritis by administering 40mg of #HUMIRA subcutaneously every 13 to 15 days,” the company noted.
“We believe this successful outcome validates Coherus’ leadership in biosimilar intellectual property and the effectiveness of our platform.
We will continue to aggressively press forward with the development and commercialization of our CHS-1420 adalimumab biosimilar consistent with our corporate strategy,” said CEO Denny Lanfear.
The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility.